-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點摘要如下： 瑞銀集團2026年第一季業績表現卓越，淨利達30億美元（年增80%），稅前利潤達40億美元（年增54%），超出市場預期。強勁的業績反映了整體成長勢頭，基礎收入成長18%，並連續第四個季度實現正向經營槓桿。瑞銀在整合瑞士信貸的過程中取得了關鍵性進展，完成了瑞士客戶帳戶的轉移，並額外節省了8億美元的毛成本。管理層表示有信心在2026年底前基本完成整合，並實現核心一級資本回報率約15%和成本收入比低於70%的退出目標。然而，有兩個重大不利因素影響了前景：擬議的瑞士資本框架變更需要額外 220 億美元的 CET1 資本，這構成了一個重大的不利因素；此外，鑑於管理層預計 2026 年第二季度淨利息收入將環比持平，地緣政治風險的上升可能會改變客戶情緒。
Related Articles
Equities
RBC Upgrades Tamboran Resources to Outperform From Sector Perform, Raises Price Target to $55 From $38, Keeps Speculative Risk
Tamboran Resources (TBN) has an average rating of buy and mean price target of $57.40 according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$TBN
Asia
Shanghai Pharmaceuticals' Profit Climbs 6.4% in Q1
Shanghai Pharmaceuticals (SHA:601607, HKG:2607) recorded a 6.4% rise in attributable profit in the first quarter of 2026 to 1.42 billion yuan from 1.33 billion yuan a year prior, according to a Wednesday Hong Kong bourse filing.The pharma company's earnings per share rose to 0.3823 yuan from 0.3595 yuan in the corresponding period of the previous fiscal year.Revenue jumped 6.4% to 75.3 billion yuan from 70.8 billion yuan in the year-ago period.
$HKG:2607$SHA:601607
Mining & Metals
CGI Q2 Adjusted Net Earnings $483.4M, up 0.6% YoY
$GIB-A.TO